View Exam | PowerPak

1. In a patient with ACS treated with a glycoprotein IIb/IIIa inhibitor and undergoing PCI, unfractionated heparin (UHF) should be given with the glycoprotein IIb/IIIa inhibitor; when should UHF be discontinued?

A. Immediately following PCI B. Within 1 hour following PCI C. Within 2 hours following PCI D. Within 4 hours following PCI

2. What is the minimum time until maximum platelet inhibition is achieved with oral P2Y₁₂inhibitors?

A. 30 – 60 minutes B. 60-90 minutes C. 60- 120 minutes D. 120- 180 minutes

3. The direct thrombin inhibitor bivalirudin is indicated for which patient populations?

A. Patients with NSTE-ACS undergoing PCI B. Patients with STEMI undergoing primary PCI C. Patients undergoing PCI for NSTE-ACS and with elevated cTn D. Bivalirudin is not indicated for any of these patients

4. Your 53-year-old male patient was treated acutely for ACS with an oral P2Y₁₂ inhibitor and aspirin. What are current recommendations regarding the duration of dual antiplatelet therapy (DAPT)?

A. Continue DAPT for 6 months B. Continue DAPT for 12 months C. Continue DAPT based upon degree of ischemic risk D. DAPT does not need to be continued in the post-acute setting

5. According to the DAPT scoring method, when does the risk of bleeding exceed the ischemic benefit in receiving aspirin and an oral P2Y₁₂ inhibitor?

A. DAPT =1 B. DAPT <2 C. DAPT >2 D. DAPT <3

6. A 65-year-old male with no evidence of atrial fibrillation is prescribed DAPT following an ischemic event. How could shared decision-making (SDM) be applied in selecting an appropriate treatment for this patient?

A. SDM can help align his situation and preferences with choice of P2Y₁₂ B. SDM can steer him towards the therapy his cardiologist recommends C. SDM can show him why he should go along with what the guidelines recommend D. SDM has no role in this scenario

Maintenance is scheduled for 8/7/2023 7:00 AM EST - 8:00 AM EST.

{{recommendationsA.Title}}

{{recommendationsB.Title}}

1. In a patient with ACS treated with a glycoprotein IIb/IIIa inhibitor and undergoing PCI, unfractionated heparin (UHF) should be given with the glycoprotein IIb/IIIa inhibitor; when should UHF be discontinued?

2. What is the minimum time until maximum platelet inhibition is achieved with oral P2Y₁₂inhibitors?

3. The direct thrombin inhibitor bivalirudin is indicated for which patient populations?

4. Your 53-year-old male patient was treated acutely for ACS with an oral P2Y₁₂ inhibitor and aspirin. What are current recommendations regarding the duration of dual antiplatelet therapy (DAPT)?

5. According to the DAPT scoring method, when does the risk of bleeding exceed the ischemic benefit in receiving aspirin and an oral P2Y₁₂ inhibitor?

6. A 65-year-old male with no evidence of atrial fibrillation is prescribed DAPT following an ischemic event. How could shared decision-making (SDM) be applied in selecting an appropriate treatment for this patient?

« Return to Activity

Maintenance is scheduled for 8/7/2023 7:00 AM EST - 8:00 AM EST.

The shopping cart is empty

Customers who Purchasedthis Activity also Purchased

{{recommendationsA.Title}}

{{recommendationsB.Title}}

1. In a patient with ACS treated with a glycoprotein IIb/IIIa inhibitor and undergoing PCI, unfractionated heparin (UHF) should be given with the glycoprotein IIb/IIIa inhibitor; when should UHF be discontinued?

2. What is the minimum time until maximum platelet inhibition is achieved with oral P2Y12 inhibitors?

3. The direct thrombin inhibitor bivalirudin is indicated for which patient populations?

4. Your 53-year-old male patient was treated acutely for ACS with an oral P2Y12 inhibitor and aspirin. What are current recommendations regarding the duration of dual antiplatelet therapy (DAPT)?

5. According to the DAPT scoring method, when does the risk of bleeding exceed the ischemic benefit in receiving aspirin and an oral P2Y12 inhibitor?

6. A 65-year-old male with no evidence of atrial fibrillation is prescribed DAPT following an ischemic event. How could shared decision-making (SDM) be applied in selecting an appropriate treatment for this patient?

« Return to Activity

Customers who Purchased
this Activity also Purchased

2. What is the minimum time until maximum platelet inhibition is achieved with oral P2Y₁₂inhibitors?

4. Your 53-year-old male patient was treated acutely for ACS with an oral P2Y₁₂ inhibitor and aspirin. What are current recommendations regarding the duration of dual antiplatelet therapy (DAPT)?

5. According to the DAPT scoring method, when does the risk of bleeding exceed the ischemic benefit in receiving aspirin and an oral P2Y₁₂ inhibitor?